GSK (NYSE:GSK – Get Free Report)‘s stock had its “buy” rating reissued by analysts at Berenberg Bank in a research report issued to clients and investors on Tuesday.
A number of other research analysts have also issued reports on the company. Jefferies Financial Group upgraded GSK from a “buy” rating to a “strong-buy” rating in a research report on Friday, July 17th. HSBC reaffirmed a “hold” rating on shares of GSK in a report on Thursday, September 10th. Citigroup began coverage on shares of GSK in a research note on Friday, July 24th. They set a “neutral” rating on the stock. Morgan Stanley restated an “underweight” rating on shares of GSK in a research report on Tuesday, August 25th. Finally, Wolfe Research began coverage on shares of GSK in a report on Friday. They issued an “outperform” rating and a $70.00 price objective for the company. Four research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $55.33.
Read Our Latest Research Report on GSK
GSK Stock Performance
GSK (NYSE:GSK – Get Free Report) last issued its quarterly earnings data on Tuesday, July 28th. The pharmaceutical company reported $1.36 earnings per share for the quarter, beating the consensus estimate of $1.27 by $0.09. The firm had revenue of $11.14 billion for the quarter, compared to the consensus estimate of $11.02 billion. GSK had a net margin of 14.56% and a return on equity of 43.23%. GSK’s quarterly revenue was up 5.3% compared to the same quarter last year. During the same period last year, the firm posted $0.47 EPS. GSK has set its FY 2026 guidance at 4.900-5.000 EPS. Equities research analysts predict that GSK will post 4.78 EPS for the current fiscal year.
Hedge Funds Weigh In On GSK
A number of hedge funds have recently modified their holdings of the stock. Security National Bank of SO Dak acquired a new position in shares of GSK in the 2nd quarter valued at $38,000. Trust Co. of Vermont acquired a new stake in shares of GSK during the second quarter valued at approximately $54,000. Philadelphia Investment Partners LLC purchased a new stake in shares of GSK in the 2nd quarter valued at approximately $70,000. Ancora Advisors LLC acquired a new position in GSK in the 2nd quarter worth approximately $71,000. Finally, Bogart Wealth LLC boosted its stake in GSK by 15.3% in the 1st quarter. Bogart Wealth LLC now owns 1,508 shares of the pharmaceutical company’s stock worth $83,000 after purchasing an additional 200 shares during the period. 15.74% of the stock is currently owned by institutional investors and hedge funds.
GSK Company Profile
GSK plc is a global biopharmaceutical company headquartered in Brentford, England. The company develops and commercializes medicines and vaccines, with research and commercial activities focused on infectious diseases, respiratory conditions, immunology, oncology and HIV. Its products are distributed across markets worldwide through healthcare providers, public health systems and pharmacies.
GSK’s portfolio includes vaccines such as Shingrix for shingles and Arexvy for respiratory syncytial virus (RSV), as well as specialty medicines including Trelegy for chronic respiratory disease and Nucala for severe asthma and related inflammatory conditions.
See Also
- Five stocks we like better than GSK
- Alphabet Introduces Gemini Agent—Can It Trigger a Breakout?
- Palantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November Earnings
- Tilray Finds a Path to Growth Without Waiting on U.S. Cannabis Reform
- Arista Networks Plugs Into All-Time Highs
Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.
